← Browse by Condition
Medical Condition
locally advanced pancreatic ductal adenocarcinoma
Total Trials
5
Recruiting Now
5
Trial Phases
Phase 1, Phase 2, Phase 2
ClinicalMetric tracks all active clinical trials for locally advanced pancreatic ductal adenocarcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.
Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.
Frequently Asked Questions — locally advanced pancreatic ductal adenocarcinoma Clinical Trials
How many clinical trials are currently recruiting for locally advanced pancreatic ductal adenocarcinoma?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for locally advanced pancreatic ductal adenocarcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for locally advanced pancreatic ductal adenocarcinoma?
locally advanced pancreatic ductal adenocarcinoma research spans Phase 1 (2 trials), Phase 2 (4 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a locally advanced pancreatic ductal adenocarcinoma clinical trial?
Eligibility criteria for locally advanced pancreatic ductal adenocarcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 2
Phase 2 4
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT05688215 Phase 1, Phase 2
Recruiting
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Enrollment
56 pts
Location
United States
Sponsor
Jonsson Comprehensive Cancer C...
NCT07157033 Phase 1, Phase 2
Recruiting
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
Enrollment
36 pts
Location
United States
Sponsor
Xerient Pharma
NCT07101679 Phase 2
Recruiting
A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer
Enrollment
23 pts
Location
China
Sponsor
West China Hospital
NCT06472037 Phase 2
Recruiting
AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC
Enrollment
30 pts
Location
China
Sponsor
Tianjin Medical University Can...
NCT06574620
Recruiting
Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
Enrollment
200 pts
Location
Canada
Sponsor
British Columbia Cancer Agency
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology